Literature DB >> 7986590

Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant.

M J Newman1, K J Munroe, C A Anderson, C I Murphy, D L Panicali, J R Seals, J Y Wu, M S Wyand, C R Kensil.   

Abstract

Subunit vaccines based on recombinant proteins have proved useful for inducing antibody responses and they are safe for widespread use because they do not contain any live components. Unfortunately, they do not typically induce the types of cell-mediated immune responses required to control viral pathogens; specifically, they do not induce CD8+ cytotoxic T lymphocyte (CTL) responses. To increase the immunogenicity of recombinant proteins, we have used the QS-21 saponin adjuvant in subunit vaccine formulations. In the current study, experimental subunit vaccine formulations containing recombinant p55gag or gp120env proteins from the mac251 strain of the simian immunodeficiency virus (SIVmac251) and the QS-21 adjuvant were used to immunize rhesus macaques. These formulations induced SIV gag- or env-specific cellular immunity that was detectable in vitro and included killer cell activity. The induction of killer cells required prior vaccination and the responses were antigen specific for the immunogens contained in the vaccine formulations. Autologous target cells were required to detect these responses, suggesting genetic restriction, and effector cells appeared to be present in both the CD4+ and CD8+ T lymphocyte subpopulations. These data suggest that the vaccine-induced killer cell activity that was detected was mediated by both CD4+ and CD8+ lymphocytes. Despite the presence of these killer cells, all of the animals became infected with the SIVmac251 on experimental challenge. These findings demonstrated that antigen-specific killer cell responses could be induced by a subunit vaccine formulated with the QS-21 saponin adjuvant. The characteristics of the responses suggested that the effector cells were T lymphocytes, expressing either CD4 or CD8.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986590     DOI: 10.1089/aid.1994.10.853

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

2.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.

Authors:  S Sasaki; T Tsuji; K Hamajima; J Fukushima; N Ishii; T Kaneko; K Q Xin; H Mohri; I Aoki; T Okubo; K Nishioka; K Okuda
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

4.  Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.

Authors:  Christiana Fogg; Shlomo Lustig; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.

Authors:  Christiana N Fogg; Jeffrey L Americo; Shlomo Lustig; John W Huggins; Scott K Smith; Inger Damon; Wolfgang Resch; Patricia L Earl; Dennis M Klinman; Bernard Moss
Journal:  Vaccine       Date:  2007-01-03       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.